Masatoshi Hasegawa
Papers
1
Total Citations
11
H-Index
1
About
Masatoshi Hasegawa is a leading figure in urologic oncology, with a focused expertise in prostate cancer treatment outcomes and patient quality of life. His research critically compares modern therapeutic modalities, particularly robot-assisted radical prostatectomy (RARP) and low-dose-rate brachytherapy (LDR-BT), to guide clinical decision-making. Hasegawa’s major contribution lies in his rigorous, patient-centered analyses that move beyond traditional oncologic endpoints to evaluate functional recovery and well-being. His most cited work, a 2023 study with 11 citations, provides pivotal comparative data on quality of life between RARP and LDR-BT, including combination therapies, helping to clarify the trade-offs patients face. This research has direct implications for informed consent and personalized treatment planning. By systematically assessing outcomes in large patient cohorts, Hasegawa has established himself as a key voice in evidence-based urology, bridging surgical and radiation oncology. His work is essential reading for clinicians and researchers striving to optimize survivorship and patient-reported outcomes in prostate cancer care.
Research Focus
Key Achievements
Top Papers
- 1